Physician profile
Frederick Okoye
NPI 1306815618
$1,978.22
in general payments reported to CMS, 2019-2025
11 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $161 · 2021: $465 · 2022: $360 · 2023: $224 · 2024: $124 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $791.18 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $406.97 | 2019-2025 | Cabenuva, Dovato |
| Janssen Biotech, INC. | $245.57 | 2019-2023 | Symtuza |
| Boston Scientific Corporation | $142.85 | 2025 | Ams 700 |
| Abbvie INC. | $125.58 | 2022-2024 | |
| Janssen Products, Lp | $101.48 | 2021-2022 | |
| Theratechnologies INC. | $69.15 | 2020-2022 | |
| Antares Pharma, INC. | $50.00 | 2023 | Tlando, Xyosted |
| Janssen Pharmaceuticals, INC | $16.42 | 2024 | Xarelto |
| Horizon Therapeutics Plc | $15.61 | 2021 | |
| Shionogi INC | $13.41 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Okoye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.